Livagen — 20mg | KEDA Khavinson Liver Peptide

Livagen is a synthetic tetrapeptide bioregulator consisting of the sequence Lys-Glu-Asp-Ala (KEDA), developed by the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology in Russia. The compound name traces to “liver” in the Khavinson nomenclature — Livagen is the tetrapeptide identified by Khavinson and colleagues as the liver tissue-derived peptide bioregulator within the broader cytomedin / cytogen peptide family. Some Russian academic literature additionally reports zinc-coordinating activity for Livagen, with research focus on peptide-metal interactions in chromatin structure and gene expression contexts. The compound has been investigated in the Russian academic literature (Bulletin of Experimental Biology and Medicine; Khavinson, Anisimov, and colleagues) for hepatic cell gene expression, chromatin biology, and age-associated cellular research endpoints in preclinical research models. Like other Khavinson short-peptide bioregulators, Livagen is studied primarily as a research tool for tissue-specific peptide pharmacology rather than as a defined receptor agonist.

Benefits (Research Focus)

• Hepatic cell biology research — studied for short-peptide bioregulator effects on hepatocyte cell populations

• Gene expression modulation — investigated for tissue-specific gene expression in liver and other cell research models

• Zinc-peptide interaction research — explored for reported zinc-coordinating activity in chromatin biology research models

• Khavinson SAR research — examined alongside other Khavinson short-peptide bioregulators for structure-activity studies

• Chromatin biology research — researched for short-peptide effects on chromatin structure and DNA accessibility endpoints

What Researchers Look At

• Hepatocyte gene expression panels and tissue-selective signaling

• Chromatin structure, histone modifications, and DNA accessibility markers

• Comparative pharmacology versus other Khavinson short-peptide bioregulators (Vesugen / KED, Pancreagen / KEDW, Prostamax / KEDP)

• Zinc-coordination chemistry and metal-peptide complex pharmacology in cell research models

• Aged-tissue versus young-tissue model responses in comparative cellular research

Quick Specs

• Form: Lyophilized white powder

• Net Peptide Content: 20 mg per vial

• Quantity: 1 vial

• Appearance: White to off-white lyophilizate

• Reconstitution: Bacteriostatic or sterile water (added by the end researcher)

• Purity: ≥99% by HPLC

• Identity: MS-verified (per COA)

• Storage: Protect from light

Identity Basics

• Compound: Livagen

• Synonyms: KEDA peptide; Lys-Glu-Asp-Ala tetrapeptide; Khavinson liver peptide bioregulator

• Class: Synthetic tetrapeptide; Khavinson bioregulator / cytomedin class; liver tissue-targeted

• Sequence: Lys-Glu-Asp-Ala (KEDA) — 4 amino acids

• Origin: Khavinson group, St. Petersburg Institute of Bioregulation and Gerontology (Russia)

• Formula / M.W.: C₁₈H₃₁N₅O₉, ~461.47 g/mol (verify against batch COA)

• CAS: Verify against supplier COA

⚠️ Disclaimer

• This product is intended for laboratory research use only.
• Not for human or veterinary use.
• Not approved for diagnostic, therapeutic, or medical applications.
• Handle using appropriate laboratory safety procedures and personal protective equipment.

COA Verification Notice: Even if the vial label or product image states a certain concentration, always go by the COA for the true verified value. We reference the COA to determine the verified concentration and purity of each product, regardless of what the label or product image indicates.

Janoshik COA — Third-Party Testing

• Livagen VPeptide Canada — December 8, 2025

• Livagen VPeptide Canada — July 21, 2026